Glucos Viaflo Baxter (Glucose)

It is commonly used to provide rapid carbohydrate energy during perioperative fasting, to treat hypoglycemia when oral intake is not feasible, as a carrier for compatible IV drugs, and as part of parenteral nutrition regimens.

Baseline blood glucose should be measured before infusion, and serial monitoring is recommended during and after the infusion, especially in patients with diabetes, impaired glucose tolerance, or critical illness.

Common reactions include mild hyperglycemia, local irritation at the infusion site, nausea, and headache. These effects are generally transient and manageable.

Serious complications may include severe hyperglycemia, anaphylactic reactions, electrolyte disturbances such as hyponatremia, and fluid overload, particularly in patients with cardiac or renal impairment.

Patients with diabetes, impaired glucose tolerance, cardiac or renal disease, liver dysfunction, or known hypersensitivity to the solution components should be monitored closely and dosing adjusted as needed.

When given concurrently with insulin, blood glucose levels can drop rapidly; therefore, insulin dosing may need adjustment and glucose levels should be closely monitored to avoid hypoglycemia.

Compatibility depends on the specific medication; it is generally safe as a carrier for compatible drugs, but incompatibility with certain hypertonic or acidic solutions should be verified before co‑administration.

Use aseptic technique, inspect the solution for particulate matter or discoloration, employ sterile connectors, and discard any unused portion after the recommended infusion period.

Regulatory details are available through the European Medicines Agency (EMA) database and the national competent authorities of EU member states where the product is marketed.